Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?

Autor: Fauchais, Anne-Laure, Prey, S., Ouatara, B., Vidal, Elisabeth, Sparsa, Agnès

Publikováno v: Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Wiley, 2010, 24 (6), pp.737-8. ⟨10.1111/j.1468-3083.2009.03455.x⟩

International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8f1250c0bae4f430025d17f2282fd1a1
https://hal-unilim.archives-ouvertes.fr/hal-00595306

Aspects cliniques et évolutifs du tétanos lié aux soins dans le service de référence du CHU d'Abidjan. (French)

Autor: Aba, T., Kra, O., Ehui, E., Tanon, K., Kacou, A., Ouatara, B., Bissagnéné, E., Kadio, A.

Publikováno v: Bulletin de la Société de Pathologie Exotique; Feb2011, Vol. 104 Issue 1, p38-41, 4p

Angiokeratoma regression in a Fabry disease after treatment with agalsidase-β: clinical effectiveness marker?

Autor: Fauchais, A. L., Prey, S., Ouatara, B., Vidal, E., Sparsa, A.

Publikováno v: Journal of the European Academy of Dermatology & Venereology; Jun2010, Vol. 24 Issue 6, p737-738, 2p, 1 Color Photograph

Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?

Autor: Fauchais AL, Prey S, Ouatara B, Vidal E, Sparsa A

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2010 Jun; Vol. 24 (6), pp. 737-8. Date of Electronic Publication: 2009 Nov 11.